Role of sildenafil in secondary pulmonary hypertension due to chronic obstructive pulmonary disease.
- Registration Number
- CTRI/2009/091/000017
- Lead Sponsor
- self
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Ambulatory patients having severe or very severe COPD according to GOLD (global initiative for chronic obstructive lung disease) classification were recruited in the study if they had: past history of smoking at least 20 pack years. They had pulmonary artery systolic pressure of more than 40 mmHg as measured by Doppler echocardiography
Patients were not included if they had: acute exacerbation of COPD in last month, history of bronchial asthma or more than 12% increase in FEV1(forced expiratory volume one second) with bronchodilator, history of primary cardiac disease or documented ischaemic heart disease, use of nitrates or other vasodilator throughout the study period, hemoglobin less than 12g/dl, any severe concomitant disease, evidence of pulmonary artery hypertension due to any other cause such as pulmonary thromboembolism, Human Immunodeficiency Virus, scleroderma, congenital heart disease etc. and de-compensated right or left heart failure.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method distance covered in six minute walk testTimepoint: at baseline, after 4 weeks and after 12 weeks
- Secondary Outcome Measures
Name Time Method YHA class of dyspnoea<br>sense of well being<br>pulmonary artery pressureTimepoint: at baseline, after 4 weeks and after 12 weeks